Display options
Cite
Hupli AMM. Medical Cannabis for Adult Attention Deficit Hyperactivity Disorder: Sociological Patient Case Report of Cannabinoid Therapeutics in Finland. Med Cannabis Cannabinoids. 2018;1(2):112-118doi: 10.1159/000495307.
Hupli, A. M. M. (2019). Medical Cannabis for Adult Attention Deficit Hyperactivity Disorder: Sociological Patient Case Report of Cannabinoid Therapeutics in Finland. Medical cannabis and cannabinoids, 1(2), 112-118. https://doi.org/10.1159/000495307
Hupli, Aleksi Mikael Markunpoika. "Medical Cannabis for Adult Attention Deficit Hyperactivity Disorder: Sociological Patient Case Report of Cannabinoid Therapeutics in Finland." Medical cannabis and cannabinoids vol. 1,2 (2019): 112-118. doi: https://doi.org/10.1159/000495307
Hupli AMM. Medical Cannabis for Adult Attention Deficit Hyperactivity Disorder: Sociological Patient Case Report of Cannabinoid Therapeutics in Finland. Med Cannabis Cannabinoids. 2018 Nov 23;1(2):112-118. doi: 10.1159/000495307. eCollection 2019 Jan. PMID: 34676327; PMCID: PMC8489316.
Copy Download .nbib Format: NLM
Share it on

Med Cannabis Cannabinoids. 2018 Nov 23;1(2):112-118. doi: 10.1159/000495307. eCollection 2019 Jan.

Medical Cannabis for Adult Attention Deficit Hyperactivity Disorder: Sociological Patient Case Report of Cannabinoid Therapeutics in Finland.

Medical cannabis and cannabinoids

Aleksi Mikael Markunpoika Hupli

Affiliations

  1. School of Social Sciences and Humanities, University of Tampere, Tampere, Finland.

PMID: 34676327 PMCID: PMC8489316 DOI: 10.1159/000495307

Abstract

This paper presents a detailed patient case report of a male patient who was diagnosed in adulthood (aged 33) with attention deficit hyperactivity disorder (ADHD) and treated initially with immediate-release methylphenidate (Ritalin® 10 mg twice daily). After experiencing adverse effects from prolonged use of this medication and afterwards other medications that were prescribed as alternatives, the patient discovered that cannabinoid therapeutics (CT) had been experimented inside the EU area to treat patients with ADHD. Subsequently, he was evaluated by a physician in Germany (June 2010) who prescribed CT (Bedrocan®, Bediol®). A Finnish neurologist later confirmed the two prescribed medicines (Bedrocan®, October 2010; Bediol®, May 2011) in the patient's own country of permanent residence (Finland). During a 5-year period of access, Bedrocan®, which mainly contains Δ9-tetrahydrocannabinol (Δ9-THC), was found to be helpful in alleviating the patient's ADHD symptoms, in particular poor tolerance to frustration, outbursts of anger, boredom, and problems related to concentration. The second CT medication, Bediol®, which contains both Δ9-THC and the phytocannabinoid cannabidiol, was found to neutralize the excessive dronabinol effects of Bedrocan® as well as zo offer other medical benefits (e.g., improved sleep). In addition to the case report, this paper also offers a brief review of the literature surrounding the medical benefits of CT for AD(H)D, which includes observational studies, clinical case reports, and one randomized clinical experiment. This paper also briefly discusses the endocannabinoid system in relation to ADHD, although more preclinical and clinical research is warranted to establish the optimal levels of cannabinoids, terpenes, and dosing regimens, which vary between different ADHD patients.

Copyright © 2018 by S. Karger AG, Basel.

Keywords: Attention deficit hyperactivity disorder; Cannabinoid therapy; Case report; Finland; Qualitative research

Conflict of interest statement

The author has no conflicts of interest to declare.

References

  1. Eur J Intern Med. 2018 Mar;49:12-19 - PubMed
  2. Harm Reduct J. 2009 Dec 03;6:35 - PubMed
  3. Neuropsychopharmacology. 2005 Mar;30(3):516-24 - PubMed
  4. Am J Med Genet B Neuropsychiatr Genet. 2008 Dec 5;147B(8):1488-94 - PubMed
  5. Neural Plast. 2007;2007:52908 - PubMed
  6. Am J Drug Alcohol Abuse. 2006;32(4):629-35 - PubMed
  7. Trends Pharmacol Sci. 2008 Apr;29(4):192-9 - PubMed
  8. Nat Med. 2003 Jan;9(1):76-81 - PubMed
  9. Curr Neuropharmacol. 2007 Dec;5(4):268-77 - PubMed
  10. Subst Use Misuse. 2014 Mar;49(4):427-34 - PubMed
  11. Neuropharmacology. 2008 Jan;54(1):141-50 - PubMed
  12. Neuroscience. 2002;109(3):451-60 - PubMed
  13. Neuropharmacology. 2009 Dec;57(7-8):715-21 - PubMed
  14. J Clin Psychiatry. 2003 Apr;64(4):459-65 - PubMed
  15. Schizophr Res. 2008 Oct;105(1-3):216-23 - PubMed
  16. Biol Psychiatry. 2006 Mar 15;59(6):508-15 - PubMed
  17. Int J Drug Policy. 2015 Mar;26(3):250-6 - PubMed
  18. Neurology. 2009 Apr 28;72(17):1526-7 - PubMed
  19. Harm Reduct J. 2007 Nov 03;4:16 - PubMed
  20. Br J Pharmacol. 2011 Aug;163(7):1344-64 - PubMed
  21. Oncotarget. 2016 Aug 23;7(34):55840-55862 - PubMed
  22. Br J Pharmacol. 2004 Apr;141(7):1193-203 - PubMed
  23. Drug Alcohol Rev. 2016 May;35(3):326-33 - PubMed
  24. Neuropharmacology. 2009 Dec;57(7-8):579-89 - PubMed
  25. Eur Neuropsychopharmacol. 2017 Aug;27(8):795-808 - PubMed
  26. J Pharmacol Exp Ther. 2000 Mar;292(3):952-9 - PubMed
  27. Neurosci Biobehav Rev. 2003 Nov;27(7):639-51 - PubMed
  28. Neuropsychopharmacology. 2009 Feb;34(3):759-66 - PubMed
  29. J Atten Disord. 2020 Sep;24(11):1487-1492 - PubMed
  30. PLoS One. 2016 May 26;11(5):e0156614 - PubMed
  31. Eur J Paediatr Neurol. 2012 Sep;16(5):422-33 - PubMed
  32. Expert Opin Ther Targets. 2006 Oct;10(5):653-63 - PubMed
  33. Chem Biodivers. 2007 Aug;4(8):1614-48 - PubMed
  34. Med Hypotheses. 2006;66(2):234-46 - PubMed
  35. Drug Alcohol Depend. 2014 Feb 1;135:88-94 - PubMed
  36. J Leukoc Biol. 2005 Dec;78(6):1192-7 - PubMed
  37. J Neurosci. 2006 Jun 21;26(25):6677-86 - PubMed

Publication Types